Cardiorenal Protection in Patients with Diabetes and CKD
Listen to leading experts discuss the new scientific statement from the AHA, “Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease,” where two newer groups of medications prescribed primarily for T2D treatment (SGLT2 inhibitors and GLP-1 receptor agonists) could significantly reduce risks associated with CKD and heart disease.
This scientific statement summarizes the current literature on the cardiorenal protective effects with SGLT2 inhibitors and GLP-1receptor agonists in patients with CKD and T2D. It reviews potential mechanistic pathways that may drive these benefits and summarizes the literature on adverse effects in patients with T2D and CKD at risk for or with established CVD.
2020 Episode 8 – Cardiorenal Protection in Patients with Diabetes and CKD
Janani Rangaswami, MD, FACP, FAHA maintains an active clinical and research practice in cardio-renal medicine at Einstein Medical Center, Philadelphia, and serves as the Associate Chair (Research) for the Internal Medicine residency program. She is a Clinical Associate Professor at Thomas Jefferson University and has won several awards from residents and fellows for clinical teaching and mentorship. She is the Vice-Chair of the Kidney Council of the AHA. She led the AHA Scientific Statements on Cardio-Renal Syndrome (2019) and the cardiorenal benefits with the newer antidiabetic agents in kidney disease (2020). She has authored several publications in cardiorenal medicine, and is the lead editor of two textbooks in this field: Textbook of Cardio Nephrology and the Textbook of Kidney Disease in the Cardiac Catheterization Laboratory.
Katherine R. Tuttle, MD, FASN, FACP, FNKF is Executive Director for Research at Providence Health Care, Co-Principal Investigator of the Institute of Translational Health Sciences and Professor of Medicine at the University of Washington. Dr. Tuttle’s major research interests are in clinical and translational science for diabetes and CKD. She has published over 200 original research contributions and served two terms as Associate Editor for the Clinical Journal of the American Society of Nephrology and the American Journal of Kidney Disease. Dr. Tuttle has received many honors and awards, including the Medal of Excellence from the American Association of Kidney Patients, Garbed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two Outstanding Clinical Faculty Awards at the University of Washington.
Muthiah Vaduganathan, MD, MPH is a Cardiologist at Brigham and Women’s Hospital and Harvard Medical School. His research focuses on drug development and clinical trials of cardiometabolic therapies. He has authored or co-authored more than 350 peer-reviewed publications. Dr. Vaduganathan serves on the editorial boards of the European Journal of Heart Failure, JACC Heart Failure (Social Media/CME Editor), and JACC (FIT/Early Career Section Editor). He participates as an investigator and Clinical Endpoints Committee member for ongoing advanced-phase trials in HF/post-MI LV dysfunction.